Discontinued — last reported Q4 '25
Zoetis Manufacturing, Research, Corporate — Restructuring Charges remained flat by 0.0% to $10.50M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 200.0%, from $3.50M to $10.50M. Over 4 years (FY 2021 to FY 2025), Manufacturing, Research, Corporate — Restructuring Charges shows an upward trend with a 18.9% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase suggests significant organizational change or cost-cutting initiatives, while a decrease indicates a period of operational stability.
This metric represents the costs associated with the reorganization, consolidation, or streamlining of manufacturing, re...
Peers in the pharmaceutical and animal health sectors report similar charges as 'Restructuring' or 'Special Items' when undergoing integration or cost-optimization programs.
zts_segment_manufacturing_research_corporate_restructuring_charges| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $21.00M | $2.00M | $22.00M | $14.00M | $42.00M |
| YoY Change | — | -90.5% | >999% | -36.4% | +200.0% |